Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks Osimertinib's impact on lung cancer survival

NCT ID NCT05103605

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes how the drug osimertinib works in real-life settings for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 274 adults in France will be followed for up to 3 years to see how long they live, how their disease changes, and their quality of life. The goal is to understand the drug's effectiveness outside of controlled clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

274 people

The number who actually took part.

Started

May 2021

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study combining a descriptive cross-sectional survey (part B) and a prospective cohort design (part A). Patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) with activating EGFR mutation initiating a treatment by osimertinib in first line (Population A) Patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated by any first line therapy (population B)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Descriptive cross-sectional survey (Population B) * Adult patients (≥ 18 years old), * Patients newly treated in first line (1L) for locally advanced or metastatic NSCLC, * Patients with activating EGFR mutation-positive, * Patient informed and not opposed to these data collection. * Prospective cohort (Population A) * Patient meeting part B inclusion criteria, * Patients newly treated in 1L by osimertinib, * Patient with common EGFR mutation-positive (exon 19 deletion or L858R mutation, alone or co-occuring with other EGFR mutations). Exclusion Criteria (Population A): * Patients enrolled in interventional clinical trials (first line treatment for a NSCLC) during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non small cell lung cancer

Contacts and locations

Locations

  • Research Site

    Abbeville, France

  • Research Site

    Aix-en-Provence, France

  • Research Site

    Angers, France

  • Research Site

    Antibes, France

  • Research Site

    Avignon, France

  • Research Site

    Bastia, France

  • Research Site

    Bayonne, France

  • Research Site

    Bordeaux, France

  • Research Site

    Bourg-en-Bresse, France

  • Research Site

    Brest, France

  • Research Site

    Cannes, France

  • Research Site

    Chambéry, France

  • Research Site

    Chauny, France

  • Research Site

    Cholet, France

  • Research Site

    Clermont-Ferrand, France

  • Research Site

    Colmar, France

  • Research Site

    Contamine-sur-Arve, France

  • Research Site

    Créteil, France

  • Research Site

    Elbeuf, France

  • Research Site

    Epagny METZ Tessy, France

  • Research Site

    Évreux, France

  • Research Site

    La Roche-sur-Yon, France

  • Research Site

    Libourne, France

  • Research Site

    Limoges, France

  • Research Site

    Lyon, France

  • Research Site

    Marseille, France

  • Research Site

    Meaux, France

  • Research Site

    Mulhouse, France

  • Research Site

    Orléans, France

  • Research Site

    Paris, France

  • Research Site

    Poitiers, France

  • Research Site

    Quimper, France

  • Research Site

    Reims, France

  • Research Site

    Rouen, France

  • Research Site

    Saint-Denis, France

  • Research Site

    Saint-Grégoire, France

  • Research Site

    Saint-Pierre, France

  • Research Site

    Saint-Priest-en-Jarez, France

  • Research Site

    Saint-Quentin, France

  • Research Site

    Toulon, France

  • Research Site

    Toulouse, France

  • Research Site

    Valenciennes, France

  • Research Site

    Vannes, France

  • Research Site

    Villefranche-sur-Saône, France

  • Research Site

    Villenave-dornon, France

  • Research Site

    Villeurbanne, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.